The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.
The Industry Scientific Advisory Board (ISAB) consists of representatives from the private companies and nonprofit foundations participating as sponsors of Alzheimer's Disease Neuroimaging Initiative (ADNI). Currently 21 companies are represented including pharmaceutical, imaging, and biotech concerns, and two foundations including the Alzheimer's Association. ISAB members meet regularly by teleconference or face-to-face at ADNI meetings and participate in the ADNI Core groups, all administered and organized by the Foundation for the National Institutes of Health. ISAB 'deliverables' include dissemination of information to sponsors, assisting in scientific review of protocols and results, initiation and consideration of "add-on" studies and analyses, and generation of consensus positions on industry priorities and concerns. Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression.
Schmidt
Mark E
ME
Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium. mschmid4@its.jnj.com
Siemers
Eric
E
Snyder
Peter J
PJ
Potter
William Z
WZ
Cole
Patricia
P
Soares
Holly
H
D000544:Alzheimer Disease / Q000175:diagnosis*; D003072:Cognition Disorders / Q000175:diagnosis; D003253:Consultants; D003952:Diagnostic Imaging; D006801:Humans; D007221:Industry; D011446:Prospective Studies; D014481:United States